<DOC>
	<DOCNO>NCT02699073</DOCNO>
	<brief_summary>The purpose study evaluate performance various tumor response criterion ( Choi RECIST1.1 criterion ) assessment regorafenib activity . Moreover , assessment tumor heterogeneity make use computed tomographic texture analysis ( CTTA )</brief_summary>
	<brief_title>Evaluation Treatment Response With CHOI RECIST Criteria CT Texture Analysis Patients With Metastatic Colorectal Cancer Treated With Regorafenib</brief_title>
	<detailed_description>This phase II study patient metastatic colorectal cancer treat regorafenib .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed date informed consent . 2 . Patients histologically proven metastatic colorectal cancer 3 . Patients previously treat , consider candidate available therapy , i.e. , fluoropyrimidinebased chemotherapy , antiVEGF therapy antiEGFR therapy ( patient RAS wildtype ) . 4 . ECOG PS = 0 1 5 . Aged 18years old 6 . Life expectancy least 3 month 7 . Adequate renal , bone marrow , liver pancreatic function : Estimated creatinine clearance ≥ 30 mL/min calculate use CockcroftGault equation Platelet count ≥ 100.000/mm3 ; hemoglobin ≥ 9 g/dL ; absolute neutrophil count ≥ 1500/mm3 . Transfusion meet inclusion criterion allow Total bilirubin ≤ 1.5 upper limit normal value ( ULN ) ; alanine aminotransferase ( ALAT ) aspartame aminotransferase ( ASAT ) ≤ 3.0 x ULN ( ≤ 5.0 x ULN patient liver involvement cancer ) ; alkaline phosphatase ( ALP ) ≤ 2.5 x ULN ( ≤ 5.0 x ULN patient liver involvement cancer and/or bone metastasis ) 8. International normalize ratio ( INR ) ≤ 1.5 x ULN partial thromboplastin time ( PTT ) activate partial thromboplastin time ( aPTT ) ≤ 1.5 x ULN unless receive treatment therapeutic anticoagulation . Patients treat anticoagulant , e.g. , heparin , allow participate provide prior evidence underlie abnormality parameter exist . Close monitoring least weekly evaluation perform INR PTT stable base predose measurement define local standard care 9 . At least one target lesion CT scan 10 . No contraindication Iodine contrast medium injection CT. 11 . For woman childbearing potential , blood urine pregnancy test perform maximum 7 day start study treatment negative result document start study treatment 12 . When applicable , i.e. , woman childbearing potential sexual activity , men sexual activity , must agree use adequate contraception enter study , least 8 week last study drug administration 13 . Registration national health care system ( CMU include ) . 1 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient inclusion trial ; plan surgical procedure within first month treatment procedure might change time regorafenib administration first month treatment 2 . Patients judicial protection ( curatorship , tutorship ) and/or deprive freedom 3 . Major surgical procedure , open biopsy significant traumatic injury within 28 day start study medication 4 . Pregnancy breastfeed 5 . Congestive heart failure ≥ New York Heart Association ( NYHA ) class 2 6 . Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) 7 . Myocardial infarction le 6 month start study medication 8 . Cardiac arrhythmia require antiarrhythmic therapy ( betablockers digoxin permit ) 9 . Uncontrolled hypertension ( systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) 10 . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication ( except adequately treat catheterrelated venous thrombosis occur one month start study medication 11 . Pleural effusion ascites cause respiratory compromise ( ≥ CTCAE grade 2 , NCICTCAE v 4.0 dyspnea ) 12 . Ongoing infection &gt; grade 2 , NCI CTCAE v 4.0 13 . Previous concurrent cancer distinct primary site histology colorectal cancer within 5 year prior inclusion , except curatively treated cervical cancer situ , nonmelanoma skin cancer superficial bladder tumor ( Ta [ noninvasive tumor ] , Tis [ carcinoma situ ] T1 [ tumor invades lamina propria ] ) 14 . Known history human immunodeficiency virus ( HIV ) infection 15 . Active hepatitis B C chronic hepatitis B C require treatment antiviral therapy 16 . Patients seizure disorder require medication 17 . History organ allograft 18 . Patients evidence history bleed diathesis , irrespective severity 19 . Any hemorrhage bleeding event ≥ Grade 3 , NCICTCAE v 4.0 within 4 week prior start study medication 20 . Nonhealing wound , nonhealing ulcer nonhealing bone fracture 21 . Dehydration grade ≥1 , NCICTCAE v 4.0 22 . Known hypersensitivity study drug , study drug class excipient formulation 23 . Interstitial lung disease ongoing sign symptoms time inclusion 24 . Persistent proteinuria &gt; 3.5 g/24 hour measure urine proteincreatinine ratio random urine sample ( ≥ Grade 3 , NCICTCAE v 4.0 ) 25 . Patients unable swallow oral medication 26 . Any malabsorption condition 27 . Unresolved toxicity high Grade 1 , NCICTCAE v 4.0 , attribute prior therapy/procedure exclude alopecia oxaliplatin induce neuropathy 28 . Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , hormonal therapy trial within 3 week 29 . Treatment investigational medicinal product within 28 day prior study entry 30 . Chronic treatment potentially interact study medication , i.e . strong CYP3A4 inducers/inhibitors , strong UGT1A9 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>regorafenib</keyword>
	<keyword>CHOI criterion</keyword>
	<keyword>RECIST criterion</keyword>
</DOC>